 |
5′-GCCATGGTTTTTTCTCAGG-3′ |
|---|---|
| Trade Name | |
| Orphan Indication | Prophylaxis for patients following documented or suspected exposure to ebolavirus |
| USA Market Approval | USA |
| USA Designation Date | 2012-10-31 00:00:00 |
| Sponsor | Sarepta Therapeutics, Inc.;215 First Street;Cambridge, Massachusetts, 02142 |
